Compare RANI & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RANI | ELTX |
|---|---|---|
| Founded | 2012 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.7M | 134.1M |
| IPO Year | 2021 | N/A |
| Metric | RANI | ELTX |
|---|---|---|
| Price | $1.40 | $8.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $8.67 | ★ $13.00 |
| AVG Volume (30 Days) | ★ 1.4M | 80.5K |
| Earning Date | 11-06-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,200,000.00 | N/A |
| Revenue This Year | $414.59 | N/A |
| Revenue Next Year | $30.15 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $4.60 |
| 52 Week High | $3.87 | $12.62 |
| Indicator | RANI | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.42 | 48.46 |
| Support Level | $1.31 | $7.81 |
| Resistance Level | $1.44 | $9.00 |
| Average True Range (ATR) | 0.08 | 0.50 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 43.14 | 35.53 |
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.